Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
- PMID: 30593284
- PMCID: PMC6309079
- DOI: 10.1186/s13073-018-0612-8
Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
Abstract
Inhibitors of poly(ADP-ribose) polymerase (PARPi) have entered the clinic for the treatment of patients with cancers that lack homology-directed DNA repair, but drug resistance remains a clinical hurdle. Recent advances in the identification of PARPi resistance mechanisms have yielded a better understanding of DNA end protection and the relevance of endogenous poly(ADP-ribose) glycohydrolase, highlighting new vulnerabilities.
Conflict of interest statement
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 
    - Gogola E, Rottenberg S, Jonkers J. Resistance to PARP inhibitors: lessons from preclinical models of BRCA-associated cancer. Annu Rev Cancer Biol. 2019; in press.
 
 
        